00010234592024Q1false8/3195http://fasb.org/us-gaap/2023#Revenues00010234592023-09-012023-11-3000010234592023-12-27xbrli:shares00010234592023-11-30iso4217:USD00010234592023-08-310001023459us-gaap:IntellectualPropertyMember2023-11-300001023459us-gaap:IntellectualPropertyMember2023-08-310001023459us-gaap:OtherIntangibleAssetsMember2023-11-300001023459us-gaap:OtherIntangibleAssetsMember2023-08-31iso4217:USDxbrli:shares0001023459simu:SoftwareMember2023-09-012023-11-300001023459simu:SoftwareMember2022-09-012022-11-300001023459simu:ServicesMember2023-09-012023-11-300001023459simu:ServicesMember2022-09-012022-11-3000010234592022-09-012022-11-300001023459simu:CommonStockAndAdditionalPaidInCapitalMember2023-08-310001023459simu:CommonStockAndAdditionalPaidInCapitalMember2022-08-310001023459simu:CommonStockAndAdditionalPaidInCapitalMember2023-09-012023-11-300001023459simu:CommonStockAndAdditionalPaidInCapitalMember2022-09-012022-11-300001023459simu:CommonStockAndAdditionalPaidInCapitalMember2023-11-300001023459simu:CommonStockAndAdditionalPaidInCapitalMember2022-11-300001023459us-gaap:RetainedEarningsMember2023-08-310001023459us-gaap:RetainedEarningsMember2022-08-310001023459us-gaap:RetainedEarningsMember2023-09-012023-11-300001023459us-gaap:RetainedEarningsMember2022-09-012022-11-300001023459us-gaap:RetainedEarningsMember2023-11-300001023459us-gaap:RetainedEarningsMember2022-11-300001023459us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-08-310001023459us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-08-310001023459us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-012023-11-300001023459us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-012022-11-300001023459us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-11-300001023459us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-11-3000010234592022-11-3000010234592022-08-310001023459us-gaap:TransferredAtPointInTimeMembersimu:SoftwareLicensesMember2023-09-012023-11-300001023459us-gaap:TransferredAtPointInTimeMembersimu:SoftwareLicensesMember2022-09-012022-11-300001023459simu:SoftwareLicensesMemberus-gaap:TransferredOverTimeMember2023-09-012023-11-300001023459simu:SoftwareLicensesMemberus-gaap:TransferredOverTimeMember2022-09-012022-11-300001023459us-gaap:TransferredOverTimeMembersimu:ConsultingServicesMember2023-09-012023-11-300001023459us-gaap:TransferredOverTimeMembersimu:ConsultingServicesMember2022-09-012022-11-300001023459simu:NorthAndSouthAmericaMember2023-09-012023-11-300001023459simu:NorthAndSouthAmericaMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-09-012023-11-30xbrli:pure0001023459simu:NorthAndSouthAmericaMember2022-09-012022-11-300001023459simu:NorthAndSouthAmericaMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-09-012022-11-300001023459us-gaap:EMEAMember2023-09-012023-11-300001023459us-gaap:ProductConcentrationRiskMemberus-gaap:EMEAMemberus-gaap:SalesRevenueNetMember2023-09-012023-11-300001023459us-gaap:EMEAMember2022-09-012022-11-300001023459us-gaap:ProductConcentrationRiskMemberus-gaap:EMEAMemberus-gaap:SalesRevenueNetMember2022-09-012022-11-300001023459srt:AsiaMember2023-09-012023-11-300001023459us-gaap:ProductConcentrationRiskMembersrt:AsiaMemberus-gaap:SalesRevenueNetMember2023-09-012023-11-300001023459srt:AsiaMember2022-09-012022-11-300001023459us-gaap:ProductConcentrationRiskMembersrt:AsiaMemberus-gaap:SalesRevenueNetMember2022-09-012022-11-300001023459us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-09-012023-11-300001023459us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-09-012022-11-300001023459us-gaap:EquipmentMember2023-11-300001023459us-gaap:ComputerEquipmentMembersrt:MinimumMember2023-11-300001023459us-gaap:ComputerEquipmentMembersrt:MaximumMember2023-11-300001023459us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2023-11-300001023459srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2023-11-300001023459simu:ClinicalPharmacologyAndPharmacometricMember2023-08-310001023459simu:QuantitativeSystemsPharmacologyMember2023-08-310001023459simu:ClinicalPharmacologyAndPharmacometricMember2023-09-012023-11-300001023459simu:QuantitativeSystemsPharmacologyMember2023-09-012023-11-300001023459simu:ClinicalPharmacologyAndPharmacometricMember2023-11-300001023459simu:QuantitativeSystemsPharmacologyMember2023-11-300001023459us-gaap:TradeNamesMember2023-11-300001023459us-gaap:NoncompeteAgreementsMembersrt:MinimumMember2023-11-300001023459us-gaap:NoncompeteAgreementsMembersrt:MaximumMember2023-11-300001023459us-gaap:NoncompeteAgreementsMember2023-11-300001023459simu:OtherInternalUseSoftwareMembersrt:MinimumMember2023-11-300001023459simu:OtherInternalUseSoftwareMembersrt:MaximumMember2023-11-300001023459simu:OtherInternalUseSoftwareMember2023-11-300001023459us-gaap:CustomerRelationshipsMembersrt:MinimumMember2023-11-300001023459us-gaap:CustomerRelationshipsMembersrt:MaximumMember2023-11-300001023459us-gaap:CustomerRelationshipsMember2023-11-300001023459simu:ERPMember2023-11-300001023459us-gaap:TradeNamesMember2023-08-310001023459us-gaap:NoncompeteAgreementsMember2023-08-310001023459simu:OtherInternalUseSoftwareMembersrt:MinimumMember2023-08-310001023459simu:OtherInternalUseSoftwareMembersrt:MaximumMember2023-08-310001023459simu:OtherInternalUseSoftwareMember2023-08-310001023459us-gaap:CustomerRelationshipsMembersrt:MinimumMember2023-08-310001023459us-gaap:CustomerRelationshipsMembersrt:MaximumMember2023-08-310001023459us-gaap:CustomerRelationshipsMember2023-08-310001023459simu:ERPMember2023-08-310001023459us-gaap:OtherIntangibleAssetsMember2023-09-012023-11-300001023459us-gaap:OtherIntangibleAssetsMember2022-09-012022-11-300001023459simu:FiniteLivedIntangibleAssetsOtherMember2023-11-300001023459us-gaap:CommercialPaperMember2023-11-300001023459us-gaap:DepositsMember2023-11-300001023459us-gaap:CommercialPaperMember2023-08-310001023459us-gaap:DepositsMember2023-08-310001023459us-gaap:DepositsMember2022-11-300001023459simu:TermAndNonassertionAgrMembersimu:TSRLMember2014-05-150001023459simu:DILIsymMembersimu:CertainDevelopedTechnologiesMember2017-06-020001023459simu:CertainIntellectualPropertyRightsMembersimu:EntelosHoldingCoMember2018-09-300001023459simu:LixoftMembersimu:CertainDevelopedTechnologiesMember2020-04-020001023459simu:ImmunetricsMembersimu:CertainDevelopedTechnologiesMember2023-06-300001023459us-gaap:IntellectualPropertyMembersimu:ImmunetricsMember2023-06-300001023459us-gaap:IntellectualPropertyMembersimu:TSRLMember2023-11-300001023459simu:DILIMemberus-gaap:IntellectualPropertyMember2023-11-300001023459simu:EntelosMemberus-gaap:IntellectualPropertyMember2023-11-300001023459us-gaap:IntellectualPropertyMembersimu:ImmunetricsMember2023-11-300001023459simu:LixoftMemberus-gaap:IntellectualPropertyMember2023-11-300001023459us-gaap:IntellectualPropertyMembersimu:TSRLMember2023-08-310001023459simu:DILIMemberus-gaap:IntellectualPropertyMember2023-08-310001023459simu:EntelosMemberus-gaap:IntellectualPropertyMember2023-08-310001023459us-gaap:IntellectualPropertyMembersimu:ImmunetricsMember2023-08-310001023459simu:LixoftMemberus-gaap:IntellectualPropertyMember2023-08-310001023459simu:IntellectualPropertysMember2023-09-012023-11-300001023459simu:IntellectualPropertysMember2022-09-012022-11-300001023459stpr:CAsrt:MinimumMember2023-11-30utr:sqft0001023459stpr:CAsrt:MinimumMember2023-09-012023-11-300001023459stpr:CA2023-11-300001023459stpr:CA2023-09-012023-11-300001023459stpr:NCsrt:MinimumMember2023-11-300001023459stpr:NCsrt:MinimumMember2023-09-012023-11-300001023459stpr:NC2023-11-300001023459stpr:NY2023-11-300001023459stpr:NY2023-09-012023-11-30simu:renewalOptions0001023459country:FR2023-11-300001023459country:FR2023-09-012023-11-300001023459stpr:PA2023-11-300001023459stpr:PA2023-09-012023-11-300001023459stpr:NYsimu:DataCenterMember2023-09-012023-11-300001023459stpr:NYsimu:DataCenterMember2023-11-3000010234592023-10-302023-10-3000010234592022-10-312022-10-3100010234592023-01-302023-01-3000010234592023-04-242023-04-2400010234592023-07-312023-07-310001023459simu:Equity2017IncentivePlanMember2016-12-230001023459simu:Equity2021IncentivePlanMember2022-10-200001023459simu:Equity2021IncentivePlanMember2023-02-090001023459simu:Equity2021IncentivePlanMember2023-10-190001023459us-gaap:SubsequentEventMembersimu:Equity2021IncentivePlanMember2024-02-080001023459us-gaap:StockOptionMember2023-11-300001023459simu:ExercisePriceRangeOneMemberus-gaap:StockOptionMember2023-09-012023-11-300001023459us-gaap:StockOptionMembersimu:ExercisePriceRangeFiveMember2023-09-012023-11-300001023459us-gaap:StockOptionMember2023-08-310001023459us-gaap:StockOptionMember2022-09-012023-08-310001023459us-gaap:StockOptionMember2023-09-012023-11-3000010234592022-09-012023-08-310001023459simu:ExercisePriceRangeOneMemberus-gaap:StockOptionMember2023-11-300001023459simu:ExercisePriceRangeTwoMemberus-gaap:StockOptionMember2023-09-012023-11-300001023459simu:ExercisePriceRangeTwoMemberus-gaap:StockOptionMember2023-11-300001023459us-gaap:StockOptionMembersimu:ExercisePriceRangeThreeMember2023-09-012023-11-300001023459us-gaap:StockOptionMembersimu:ExercisePriceRangeThreeMember2023-11-300001023459simu:ExercisePriceRangeFourMemberus-gaap:StockOptionMember2023-09-012023-11-300001023459simu:ExercisePriceRangeFourMemberus-gaap:StockOptionMember2023-11-300001023459us-gaap:StockOptionMembersimu:ExercisePriceRangeFiveMember2023-11-300001023459simu:NonManagementDirectorsMember2023-09-012023-11-3000010234592022-12-292022-12-2900010234592023-01-112023-01-1100010234592023-01-1100010234592023-05-202023-05-2000010234592023-05-210001023459us-gaap:CustomerConcentrationRiskMembersimu:InternationalSalesMemberus-gaap:SalesMember2023-09-012023-11-300001023459us-gaap:CustomerConcentrationRiskMembersimu:InternationalSalesMemberus-gaap:SalesMember2022-09-012022-11-300001023459us-gaap:CustomerConcentrationRiskMembersimu:Customer1Memberus-gaap:SalesMember2023-09-012023-11-300001023459us-gaap:CustomerConcentrationRiskMembersimu:AnotherCustomer2Memberus-gaap:SalesMember2023-09-012023-11-300001023459us-gaap:CustomerConcentrationRiskMembersimu:AnotherCustomer3Memberus-gaap:SalesMember2023-09-012023-11-300001023459us-gaap:CustomerConcentrationRiskMembersimu:Customer1Memberus-gaap:SalesMember2022-09-012022-11-300001023459us-gaap:CustomerConcentrationRiskMembersimu:AnotherCustomer2Memberus-gaap:SalesMember2022-09-012022-11-300001023459us-gaap:CustomerConcentrationRiskMembersimu:AnotherCustomer3Memberus-gaap:SalesMember2022-09-012022-11-300001023459us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMembersrt:MinimumMember2023-09-012023-11-300001023459us-gaap:CustomerConcentrationRiskMembersrt:MaximumMemberus-gaap:AccountsReceivableMember2023-09-012023-11-300001023459us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMembersrt:MinimumMember2022-09-012022-11-300001023459us-gaap:CustomerConcentrationRiskMembersrt:MaximumMemberus-gaap:AccountsReceivableMember2022-09-012022-11-30simu:segment0001023459simu:SoftwareSegmentMember2023-09-012023-11-300001023459simu:ServicesSegmentMember2023-09-012023-11-300001023459us-gaap:ProductConcentrationRiskMembersimu:SoftwareSegmentMemberus-gaap:SalesRevenueNetMember2023-09-012023-11-300001023459us-gaap:ProductConcentrationRiskMembersimu:ServicesSegmentMemberus-gaap:SalesRevenueNetMember2023-09-012023-11-300001023459simu:SoftwareSegmentMember2022-09-012022-11-300001023459simu:ServicesSegmentMember2022-09-012022-11-300001023459us-gaap:ProductConcentrationRiskMembersimu:SoftwareSegmentMemberus-gaap:SalesRevenueNetMember2022-09-012022-11-300001023459us-gaap:ProductConcentrationRiskMembersimu:ServicesSegmentMemberus-gaap:SalesRevenueNetMember2022-09-012022-11-300001023459simu:ImmunetricsMembersimu:ServicesSegmentMember2023-09-012023-11-300001023459us-gaap:SubsequentEventMember2024-01-032024-01-030001023459us-gaap:SubsequentEventMember2024-02-052024-02-05

Commission file number: 001-32046

(Name of registrant as specified in its charter)

(Address of principal executive offices including zip code)

(Registrant’s telephone number, including area code)

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

The number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of December 27, 2023, was 19,967,077.

Table of Contents

Item 1.    Condensed Consolidated Financial Statements

(Unaudited)

(Unaudited)

Organization

Simulations Plus, Inc. (“Simulations Plus”) was incorporated on July 17, 1996. In September 2014, Simulations Plus acquired all of the outstanding equity interests of Cognigen Corporation (“Cognigen”) and Cognigen became a wholly owned subsidiary of Simulations Plus. In June 2017, Simulations Plus acquired DILIsym Services, Inc. (“DILIsym”) as a wholly owned subsidiary. In April 2020, Simulations Plus acquired Lixoft, a French société par actions simplifiée (“Lixoft” or “SLP France”), as a wholly owned subsidiary pursuant to a stock purchase and contribution agreement. In June 2023, Simulations Plus acquired Immunetrics, Inc. (“Immunetrics”) as a wholly owned subsidiary through a reverse triangular merger. (Simulations Plus together with its subsidiaries, collectively, the “Company,” “we,” “us,” “our”).

Effective September 1, 2021, the Company merged both Cognigen and DILIsym with and into Simulations Plus through short-form mergers (the “Mergers”). To effectuate the Mergers, the Company filed Certificates of Ownership with the Secretaries of State of the states of Delaware (Cognigen’s and DILIsym’s state of incorporation) and California (Simulation Plus’ state of incorporation). Consummation of the Mergers was not subject to approval of the Company’s stockholders and did not impact the rights of the Company’s stockholders.

On December 20, 2022, Simulations Plus International, Inc. (“SLPI”), a Delaware corporation, was created as a wholly owned subsidiary of Simulations Plus in order to facilitate future international acquisitions, if any, and global integrations. In furtherance of this objective, the Company added the trade name “SLP France” to Lixoft, and on April 25, 2023, Simulations Plus transferred its ownership of SLP France to SLPI pursuant to a contribution and acceptance agreement, resulting in SLP France becoming a wholly owned subsidiary of SLPI. The transfer did not impact the rights of the Company’s stockholders.

Effective September 1, 2023, the Company merged Immunetrics with and into Simulations Plus through a short-form merger (the “Merger”). To effectuate the Merger, the Company filed Certificates of Ownership with the Secretaries of State of the states of Delaware (Immunetrics’ state of incorporation) and California (Simulation Plus’ state of incorporation). Consummation of the Merger was not subject to approval of the Company’s stockholders and did not impact the rights of the Company’s stockholders.

At the beginning of fiscal year 2024, in order to create a more integrated and cohesive company, the Company reorganized its internal structuring to move away from divisions based on its prior acquisitions and to instead divide the internal structure into business units organized around key product and service offerings that the Company provides, which include:

•Clinical Pharmacology and Pharmacometrics (“CPP”);

•Quantitative Systems Pharmacology (“QSP”);

•Physiologically based pharmacokinetics (“PBPK”);

•Cheminformatics; and

•Regulatory Strategies.

Lines of Business

We are a premier developer of drug discovery and development software for modeling and simulation, and for the prediction of molecular properties utilizing both artificial-intelligence-based and machine-learning-based technologies. We also provide consulting services ranging from early drug discovery through preclinical and clinical development analysis and for submissions to regulatory agencies. Our software and consulting services are provided to major pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and academic and regulatory agencies worldwide for use in the conduct of industry-based research.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of Simulations Plus and its wholly owned operating subsidiaries, SLPI and SLP France. All significant intercompany accounts and transactions are eliminated in consolidation.

Use of Estimates

Our financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. Actual results could differ from those estimates.

Reclassifications

Certain numbers in the prior year have been reclassified to conform to the current year’s presentation.

We generate revenue primarily from the sale of software licenses and by providing consulting services to the pharmaceutical industry for drug development.

In accordance with ASC 606, we determine revenue recognition through the following steps:

i.Identification of the contract, or contracts, with a customer

ii.Identification of the performance obligations in the contract

iii.Determination of the transaction price

v.Recognition of revenue when, or as, we satisfy a performance obligation

The following is a description of principal activities from which the Company generates revenue. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. Standalone selling prices are determined based on the prices at which the Company separately sells its services or goods.

Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and unbilled amounts that will be recognized as revenue in future periods. As of November 30, 2023, remaining performance obligations were $10.3 million. Ninety-five percent of the remaining performance obligations are expected to be recognized over the next 12 months, with the remainder expected to be recognized thereafter. Remaining performance obligations estimates are subject to change and are affected by several factors, including contract terminations and changes in the scope of contracts.

The components of disaggregation of revenue for the three months ended November 30, 2023 and 2022 were as follows:

In addition, the Company allocates revenues to geographic areas based on the locations of its customers. Geographical revenues for the three months ended November 30, 2023 and 2022 were as follows:

We receive payments from customers based upon contractual billing schedules, while we recognize revenue when, or as, we satisfy our performance obligations. This timing difference results in accounts receivable, contract assets, and contract liabilities. We record accounts receivable when the right to consideration becomes unconditional. We record a contract asset if the right to consideration is conditioned on something other than the passage of time, such as our future performance. Contract assets are included in prepaid expenses and other current assets on our condensed consolidated balance sheets. We record a contract liability when we have an obligation to transfer goods or services to a customer for which we have either received consideration or a payment is due from a customer. We refer to contract liabilities as deferred revenue on our condensed consolidated balance sheets.

Contract asset balances as of November 30, 2023, and August 31, 2023, were $2.9 million and $2.7 million, respectively.

During the three months ended November 30, 2023, the Company recognized $2.2 million of revenue that was included in contract liabilities as of August 31, 2023, and during the three months ended November 30, 2022, the Company recognized $1.9 million of revenue that was included in contract liabilities as of August 31, 2022.

Sales commissions earned by our sales force and our commissioned sales representatives are considered incremental and recoverable costs of obtaining a contract with a customer. We apply the practical expedient as described in ASC 340-40-25-4 to expense costs as incurred for sales commissions, since the amortization period of the asset that we otherwise would have recognized is one year or less. This expense is included in the condensed consolidated statements of operations and comprehensive income as selling and marketing expense.

Cash and Cash Equivalents

For purposes of the statements of cash flows, we consider all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

Accounts Receivable and Allowance for Credit Losses The Company extends credit to its customers in the normal course of business.

The Company evaluates its allowance for credit losses based on its estimate of the collectability of its trade accounts receivable. As part of this assessment, the Company considers various factors including the financial condition of the individual companies with which it does business, the aging of receivable balances, historical experience, changes in customer payment terms, current market conditions, and reasonable and supportable forecasts of future economic conditions. In times of economic turmoil, the Company’s estimates and judgments with respect to the collectability of its receivables is subject to greater uncertainty than in more stable periods. Accounts receivable balances will be charged off against the allowance for credit losses after all means of collection have been exhausted and the potential for recovery is considered remote.

The activity in the allowance for credit losses related to our trade receivables is summarized as follows:

Investments

The Company may invest excess cash balances in short-term and long-term marketable debt securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds, and/or commercial paper within the parameters of our Investment Policy and Guidelines. The Company accounts for its investments in marketable securities in accordance with ASC 320, Investments – Debt and Equity Securities. This statement requires debt securities to be classified into three categories:

Held-to-maturity—Debt securities that the entity has the positive intent and ability to hold to maturity are measured at amortized cost and are presented at the net amount expected to be collected. Any change in the allowance for credit losses during the period is reflected in earnings. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security.

Trading Securities—Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings.

Available-for-Sale—Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value. For available-for-sale debt securities in an unrealized-loss position, we evaluate as of the balance sheet date whether the unrealized losses are attributable to a credit loss or other factors. The portion of unrealized losses related to a credit loss is recognized in earnings, and the portion of unrealized loss not related to a credit loss is recognized in other comprehensive income (loss).

We classify our investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. We subsequently reassess the appropriateness of that classification at each reporting date. During the three months ended November 30, 2023 and for the year ended August 31, 2023, all of our investments were classified as held-to-maturity.

Software development costs are capitalized in accordance with ASC 985-20. Capitalization of software development costs begins upon the establishment of technological feasibility and is discontinued when the product is available for sale.

The establishment of technological feasibility and the ongoing assessment for recoverability of capitalized software development costs require considerable judgment by management with respect to certain external factors including, but not limited to, technological feasibility, anticipated future gross revenue, estimated economic life, and changes in software and hardware technologies. Capitalized software development costs are comprised primarily of salaries and direct payroll-related costs and the purchase of existing software to be used in our software products.

Amortization of capitalized software development costs is calculated on a product-by-product basis on the straight-line method over the estimated economic life of the products (not to exceed five years). Amortization of software development costs amounted to $0.4 million and $0.4 million for the three months ended November 30, 2023 and 2022, respectively. We expect future amortization expense to vary due to increases in capitalized computer software development costs.

We test capitalized computer software development costs for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Property and Equipment

Property and equipment are recorded at cost, or fair market value for property and equipment acquired in business combinations, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives as follows:

Maintenance and minor replacements are charged to expense as incurred. Gains and losses on disposals are included in the results of operations.

Internal-use Software

We have capitalized certain internal-use software costs in accordance with ASC 350-40, which are included in intangible assets. The amortization of such costs is classified as general and administrative expenses on the condensed consolidated statements of operations. Maintenance of and minor upgrades to internal-use software are also classified as general and administrative expenses as incurred.

Leases

We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities (current and long-term) in our condensed consolidated balance sheets.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we generally use our incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at the commencement date. The operating lease ROU asset also includes any lease payments made at or before the commencement date and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.

Supplemental balance sheet information related to operating leases was as follows as of November 30, 2023:

We perform valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination and recognize the assets acquired and liabilities assumed at their acquisition-date fair value. Acquired intangible assets include customer relationships, software, trade names, and noncompete agreements. We determine the appropriate useful life by performing an analysis of expected cash flows based on historical experience of the acquired businesses. Finite-lived intangible assets are amortized over their estimated useful lives using the straight-line method, which approximates the pattern in which the majority of the economic benefits are expected to be consumed. Finite-lived intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.

Goodwill represents the excess of the cost of an acquired entity over the fair value of the acquired net assets. Goodwill and indefinite-lived intangible assets are tested for impairment annually or when events or circumstances change that would indicate that they might be impaired. Events or circumstances that could trigger an impairment review include, but are not limited to, a significant adverse change in legal factors or in the business climate, an adverse action or assessment by a regulator, unanticipated competition, a loss of key personnel, significant changes in the manner of our use of the acquired assets or the strategy for our overall business, significant negative industry or economic trends, or significant underperformance relative to expected historical or projected future results of operations.

Goodwill and the other assets and liabilities acquired as part of the Immunetrics acquisition have been assigned to a separate reporting unit.

Goodwill and intangible assets are tested for impairment at the reporting unit level, which is either one level below or the same level as an operating segment.

Consistent with the reorganization of our internal structuring to move away from divisions based on our prior acquisitions to business units organized around key product and service offerings, as of November 30, 2023, our reporting units now include the following business units:

•Clinical Pharmacology and Pharmacometrics, or CPP;

•Quantitative Systems Pharmacology, or QSP;

•Physiologically-based pharmacokinetics, or PBPK;

•Cheminformatics; and

•Regulatory Strategies.

As part of this reorganization, we also took the opportunity to evaluate our departmental structure with a focus on continuing to improve operational performance and profitability. Accordingly, we moved all services personnel into cost of revenues departments, all R&D personnel into R&D expense departments, all sales and marketing personnel into selling and marketing expense departments, and all overhead personnel into general and administrative expense departments. To provide investors improved visibility to our progress, we also decided to report separately our selling and marketing expenses from our general and administrative expenses.

Reconciliation of Goodwill for the three months ended November 30, 2023:

The following table summarizes other intangible assets as of November 30, 2023:

The following table summarizes other intangible assets as of August 31, 2023:

Total amortization expense for the three months ended November 30, 2023 and 2022 was $0.2 million and $0.1 million, respectively.

Estimated future amortization of finite-lived intangible assets for the next five fiscal years is as follows:

Fair Value of Financial Instruments

Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:

For certain of our financial instruments, including accounts receivable, accounts payable, and accrued compensation and other accrued expenses, the carrying amounts are representative of their fair value due to their short maturities.

We invest a portion of our excess cash balances in short-term debt securities. Investments at November 30, 2023, consisted of corporate bonds and term deposits with maturities remaining of less than 12 months. Under the fair-value hierarchy, the fair market values of the Company’s cash equivalents and investments are Level I. We may also invest excess cash balances in certificates of deposit, money market accounts, government-sponsored enterprise securities, and/or commercial paper. We account for our investments in accordance with ASC 320, Investments – Debt and Equity Securities. As of November 30, 2023, all investments were classified as held-to-maturity securities, as we have the positive intent and ability to hold these securities until maturity. We believe unrealized losses on investments were primarily caused by rising interest rates rather than changes in credit quality, and, accordingly, we have not recorded an allowance for credit losses on our debt securities as of November 30, 2023, and August 31, 2023.

The following tables summarize our short-term investments as of November 30, 2023, and August 31, 2023:

As of November 30, 2023, the Company had a liability for contingent consideration related to its acquisition of Immunetrics. The fair value measurement of the contingent consideration obligations are determined using Level 3 inputs. The fair value of contingent consideration obligations are based on a discounted cash flow model using a probability-weighted income approach. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in markets. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. Changes in the fair value of the contingent consideration obligations are recorded in the Company’s Condensed Consolidated Statement of Operations.

The following is a reconciliation of contingent consideration at fair value:

Business Combination

The acquisition method of accounting for business combinations requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which we may adjust the provisional amounts recognized for a business combination).

Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, and any noncontrolling interests in an acquiree, generally at the acquisition-date fair value. We measure goodwill as of the acquisition-date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed. Costs that we incur to complete the business combination, such as investment banking, legal, and other professional fees, are not considered part of consideration, and we recognize such costs as general and administrative expenses as they are incurred. Under the acquisition method, we also account for acquired company restructuring activities that we initiate separately from the business combination.

Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date, and we record those adjustments to our financial statements. We apply those measurement-period adjustments that we determine to be material retrospectively to comparative information in our financial statements, including adjustments to depreciation and amortization expense.

Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred-tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period, and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred-tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. This accounting applies to all of our acquisitions regardless of acquisition date.

Research and development costs are charged to expense as incurred until technological feasibility has been established. These costs include salaries, laboratory experiments, and purchased software that was developed by other companies and incorporated into, or used in the development of, our final products.

We account for income taxes in accordance with ASC 740, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.

Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.

Intellectual property

In May 2014, we entered into a termination and non-assertion agreement with TSRL, Inc., pursuant to which the parties agreed to terminate an exclusive software licensing agreement entered into between the parties in 1997. As a result, the Company obtained a perpetual right to use certain source code and data, and TSRL relinquished any rights and claims to any GastroPlus products and to any claims, royalties, or other payments under that 1997 agreement. We agreed to pay TSRL total consideration of $6.0 million, which is being amortized over 10 years under the straight-line method.

In June 2017, as part of the acquisition of DILIsym, the Company acquired certain developed technologies associated with the drug-induced liver disease (DILI). These technologies were valued at $2.9 million and are being amortized over 9 years under the straight-line method.

In September 2018, we purchased certain intellectual property rights of Entelos Holding Company. The cost of $0.1 million is being amortized over 10 years under the straight-line method.

In April 2020, as part of the acquisition of Lixoft, the Company acquired certain developed technologies associated with the Lixoft scientific software. These technologies were valued at $8.0 million and are being amortized over 16 years under the straight-line method.

In June 2023, we purchased certain developed technology of Immunetrics. The cost of $1.1 million is being amortized over 5 years under the straight-line method.

The following table summarizes intellectual property as of November 30, 2023:

The following table summarizes intellectual property as of August 31, 2023:

Total amortization expense for intellectual property agreements for the three months ended November 30, 2023 and 2022 was $0.4 million and $0.3 million, respectively.

Estimated future amortization of intellectual property for the next five years is as follows:

Earnings per Share

We report earnings per share in accordance with ASC 260. Basic earnings per share is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding. Diluted earnings per share is computed similarly to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The components of basic and diluted earnings per share for the three months ended November 30, 2023 and 2022 were as follows:

Compensation costs related to stock options are determined in accordance with ASC 718. Compensation cost is calculated based on the grant-date fair value estimated using the Black-Scholes pricing model and then amortized on a straight-line basis over the requisite service period. Stock-based compensation costs related to stock options, not including shares issued to directors for services, was $1.3 million and $0.9 million for the three months ended November 30, 2023 and 2022, respectively.

Impairment of Long-lived Assets

We account for the impairment and disposition of long-lived assets in accordance with ASC 360. Long-lived assets to be held and used are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable. We measure recoverability by comparing the carrying amount of an asset to the expected future undiscounted net cash flows generated by the asset. If we determine that the asset may not be recoverable, or if the carrying amount of an asset exceeds its estimated future undiscounted cash flows, we recognize an impairment charge to the extent of the difference between the fair value and the asset's carrying amount. No impairment losses were recorded during the three months ended November 30, 2023 and 2022, respectively.

Recently Issued Accounting Standards

In October, 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-06 - Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative ("ASU 2023-06"). ASU 2023-06 incorporates 14 of the 27 disclosure requirements published in SEC Release No. 33-10532 - Disclosure Update and Simplification into various topics within the Accounting Standards Codification ("ASC"). ASU 2023-06's amendments represent clarifications to, or technical corrections of, current requirements. For SEC registrants, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. Early adoption is prohibited. The Company does not expect ASU 2023-06 to have a material effect on its condensed consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the ASU to determine its impact on the Company’s disclosures.

Recently Adopted Accounting Standards

In October 2021, the FASB issued ASU 2021-08, Business Combinations - Accounting for contract assets and contract liabilities from contracts with customers (Topic 805), which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with Revenues from contracts with customers (Topic 606). For public companies, the guidance is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted the guidance during fiscal year 2023. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements.

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), which requires business entities to disclose information about transactions with a government that are accounted for by applying a grant or contribution model by analogy (for example, IFRS guidance in IAS 20 or guidance on contributions for not-for-profit entities in ASC 958-605). For transactions within scope, the new standard requires the disclosure of information about the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line items affected by the transaction. The new guidance is effective for annual reporting periods beginning after December 15, 2021. The Company adopted the guidance during fiscal year 2023. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements.

The components of other income for the three months ended November 30, 2023 and 2022, were as follows:

Leases

We lease 4,200 square feet of office space in Lancaster, California, where our corporate headquarters are located. The lease term extends to April 30, 2028 and the base rent is $8 thousand per month with an annual increase of 3%. The lease agreement gives the Company the right, upon 180 days prior notice, to opt out of all or part of the last three years of the lease term with no penalty.

We lease 1,510 square feet of office space in Durham, North Carolina. The lease term extends to September 30, 2026, and the base rent is $4 thousand per month with an annual increase of 3%. The amended lease agreement gives the Company the right, upon 9 months prior notice, to extend the lease for 60 months.

We lease 4,317 square feet of office space in Buffalo, New York. The lease term extends to November 30, 2026, and the base rent is $7 thousand per month with an annual 2% increase. The lease agreement provides the Company with two five-year renewal options and the right to terminate the lease with one year’s prior written notice with certain penalties.

We lease 2,300 square feet of office space in Paris, France. The lease term extends to November 30, 2024, and the rent is $5 thousand per month, which amount is subject to adjustment each December based on a consumer price index.

We lease 7,141 square feet of office space in Pittsburgh, Pennsylvania. The lease term extends to May 31, 2025, and the base rent is $10 thousand per month. The lease agreement provides the Company with one five-year renewal option.

We have a data center colocation space in Buffalo, New York, with a lease term through November 30, 2026, and rent of $4 thousand per month with an annual 3% increase.

Rent expense, including common area maintenance fees for the three months ended November 30, 2023 and 2022 was $0.1 million and $0.1 million, respectively.

Lease liability maturities as of November 30, 2023, were as follows:

Employment Agreements

In the normal course of business, the Company has entered into employment agreements with certain of its executive officers that may require compensation payments upon termination.

We follow guidance issued by the FASB with regard to our accounting for uncertainty in income taxes recognized in the financial statements. Such guidance prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position, and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to income tax expense. We file income tax returns with the IRS and various state jurisdictions as well as with the countries of India and France. Our federal income tax returns for fiscal years 2020 through 2023 are open for audit, and our state tax returns for fiscal years 2019 through 2023 remain open for audit.

Our review of prior year tax positions using the criteria and provisions presented in guidance issued by FASB did not result in a material impact on our financial position or results of operations.

Litigation

We are not a party to any legal proceedings and are not aware of any pending or threatened legal proceedings of any kind.

Shares Outstanding

Shares of Company's common stock outstanding for the three months ended November 30, 2023 and 2022 were as follows:

Dividends

The Company’s Board of Directors declared cash dividends during the fiscal years 2024 and 2023. The details of dividends paid are in the following tables:

Stock Option Plans

On December 23, 2016, the Company’s Board of Directors adopted, and on February 23, 2017, its shareholders approved, the Company’s 2017 Equity Incentive Plan (the “2017 Plan”), under which a total of 1.0 million shares of common stock were initially reserved for issuance. The 2017 plan would have terminated pursuant to its terms in December 2026; however, the 2017 Plan was replaced by the Company’s 2021 Plan (as defined below), and as a result, no further issuances of shares may be made under the 2017 Plan.

On April 9, 2021, the Company’s Board of Directors adopted, and on June 23, 2021, its shareholders approved, the Company’s 2021 Equity Incentive Plan (the “2021 Plan,” and together with the 2017 Plan, the “Plans”), under which a total of 1.3 million shares of common stock were initially reserved for issuance. On October 20, 2022, the Company’s Board of Directors approved, and on February 9, 2023, its shareholders approved, an amendment to the 2021 Plan to increase the number of shares of common stock authorized for issuance thereunder from 1.3 million shares to 1.55 million shares of common stock of the Company. The 2021 Plan will terminate in 2031.

On October 19, 2023, the Company’s Board of Directors approved, subject to shareholder approval, an amendment to the 2021 Plan to increase the number of shares of common stock authorized for issuance thereunder from 1.55 million shares to 2.5 million shares of common stock of the Company (the “Plan Amendment”). The Plan Amendment will be presented to the Company’s shareholders for approval at its 2024 Annual Meeting of Shareholders, to be held on February 8, 2024. If approved by the Company’s shareholders, the Plan Amendment will be effective as of the date of such approval. If the Plan Amendment is not approved by the Company’s shareholders, the Plan Amendment will not become effective, and the number of shares of common stock authorized for issuance under the 2021 Plan will remain at 1.55 million shares.

As of November 30, 2023, employees and directors of the Company held Qualified Incentive Stock Options (“ISOs”) and Non-Qualified Stock Options (“NQSOs”) to purchase an aggregate of 1.9 million shares of common stock at exercise prices ranging from $6.85 to $66.14 per share.

The following tables summarize information about stock options:

The total grant-date fair value of nonvested stock options as of November 30, 2023, was $22.1 million and is amortizable over a weighted-average period of 3.67 years.

The fair value of these options was estimated at the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. In addition, option-valuation models require the input of highly subjective assumptions, including the expected stock price volatility.

The following table summarizes the fair value of the options, including both ISOs and NQSOs, granted during the three month period ended November 30, 2023 and fiscal year 2023:

The exercise prices for the options outstanding at November 30, 2023, ranged from $6.85 to $66.14, and the information relating to these options are as follows:

(in thousands except prices and weighted-average amounts)

During the three months ended November 30, 2023, we issued 4,255 shares of stock valued at $0.2 million to our nonmanagement directors as compensation for board-related duties.

The Company's par-value common stock and additional paid-in capital as of November 30, 2023, were $11 thousand and $146.6 million, respectively.

Share Repurchases

No share repurchases were made during the three months ended November 30, 2023 and 2022.

On December 29, 2022, our Board of Directors authorized and approved a share repurchase program for up to $50 million of the outstanding shares of our common stock, and on January 11, 2023, we entered into an accelerated share repurchase agreement (the “ASR Agreement”) with Morgan Stanley & Co. LLC (“Morgan Stanley”) to repurchase an aggregate of $20 million of our outstanding shares of common stock as part of the share repurchase program, which was settled in full in May 2023. The share repurchase program has no expiration date but may be terminated at any time at our Board of Directors’ discretion.

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents, trade accounts receivable, and short-term investments. The Company holds cash and cash equivalents with balances that exceed FDIC insured limits. Cash maintained in excess of these limits is on deposit with a large, national bank. Accordingly, the Company does not have depository exposure to regional banks. In addition, the Company holds cash at a bank in France that is not FDIC-insured. Historically, the Company has not experienced any losses in such accounts, and management believes that the financial institutions at which its cash is held are stable; however, no assurances can be provided. While the Company may be exposed to credit losses due to the nonperformance of its counterparties, the Company does not expect the settlement of these transactions to have a material effect on its results of operations, cash flows, or financial condition.

Revenue concentration shows that international sales accounted for 25% and 29% of revenue for the three months ended November 30, 2023 and 2022, respectively. Our three largest customers in terms of revenue accounted for 8%, 8%, and 5% of revenue, respectively, for the three months ended November 30, 2023. Our three largest customers in terms of revenue accounted for 8%, 3%, and 3% of revenue, respectively, for the three months ended November 30, 2022.

Accounts receivable concentrations show that our three largest customers in terms of accounts receivable each comprised between 7% and 9% of accounts receivable as of November 30, 2023; our three largest customers in terms of accounts receivable comprised between 4% and 12% of accounts receivable as of November 30, 2022.

We operate in the biosimulation market, which is highly competitive and changes rapidly. Our operating results could be significantly affected by our ability to develop new products and find new distribution channels for new and existing products.

The Company applies ASC 280, Segment Reporting, in determining reportable segments. The Company has two reportable segments: Software and Services. Segment information is presented in the same manner that the chief operating decision maker (“CODM”) reviews certain financial information based on these reportable segments. The CODM reviews revenue and gross profit for both of the reportable segments. Gross profit is defined as revenue less cost of revenue incurred by the segment.

No operating segments have been aggregated to form the reportable segments. The Company does not allocate assets at the reportable segment level, as these are managed on an entity-wide group basis and, accordingly, the Company does not report asset information by segment. The Company does not allocate operating expenses that are managed on an entity-wide group basis and, accordingly, the Company does not allocate and report operating expenses at a segment level. There are no internal revenue transactions between the Company’s segments.

The following tables summarize the results for each segment for the three months ended November 30, 2023 and 2022:

Our software business and services business represented 52% and 48% of total revenue, respectively, for the three months ended November 30, 2023.

Our software business and services business represented 51% and 49% of total revenue, respectively, for the three months ended November 30, 2022.

The increase in the cost of revenues for our Services segment and corresponding decline in gross margin for the three months ended November 30, 2023 compared to the three months ended November 30, 2022 is driven by $1.2 million from the reorganization of our internal structure from divisions based on prior acquisitions to business units organized around key product and service offerings and $0.4 million from the acquisition of Immunetrics, which contributed to our services headcount. Gross margin would have been 49% during the three months ended November 30, 2022 under the current organization structure. The new business unit structure is designed to optimize the utilization of our scientific talent in support of our revenue growth objectives.

We maintain a 401(k) Plan for eligible employees. We make matching contributions equal to 100% of the employee’s elective deferral, not to exceed 4% of the employee’s gross salary. We contributed $0.1 million and $0.1 million for the three months ended November 30, 2023 and 2022, respectively.

The Company receives government assistance in the form of cash grants which vary in size, duration, and conditions from domestic governmental agencies. Accounting for the grant revenue does not fall under ASC 606, Revenue from Contracts with Customers, as the Government will not benefit directly from our offerings. For government assistance in which no specific US GAAP applies, the Company accounts for such transactions as revenue and by analogy to a grant model. Under such model, the Company recognizes the impact of the government assistance on the Condensed Consolidated Statements of Income upon complying with the conditions of the grant. The grant revenue is recognized on a gross basis. The Company's accounting policy is to recognize a benefit to the income statement over the duration of the program when the conditions attached to the grant are achieved. If conditions are not satisfied, the grants are often subject to reduction, repayment, or termination. The Company classifies the impact of government assistance on the Condensed Consolidated Statements of Income as Services Revenue.

During the three months ended November 30, 2023, government assistance received primarily consisted of the following:

The Company received assistance from domestic governmental agencies to provide reimbursement for various costs incurred for research and development. These include direct grant awards and subawards. The grants awarded are currently set to expire at various dates through 2025. During the three months ended November 30, 2023 and 2022, the Company recognized $0.4 million and $0.3 million, respectively, within Services revenues on the Condensed Consolidated Statements of Operations and Comprehensive Income related to such assistance. To the extent amounts have been earned but not yet funded, the amounts are in Accounts Receivable. Computer equipment allowable by the grants is classified under Fixed Assets. Subawards due to unrelated entities are classified under Accrued Expenses.

Dividend Declared

On Thursday, January 3, 2024, our Board of Directors declared a quarterly cash dividend of $0.06 per share to our shareholders. The dividend in the amount of approximately $1.2 million will be distributed on Monday, February 5, 2024, for shareholders of record as of Monday, January 29, 2024.

This document and the documents incorporated in this document by reference contain forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact contained in this document and the materials accompanying this document are forward-looking statements.

The forward-looking statements are based on the beliefs of our management, as well as assumptions made by and information currently available to our management. Frequently, but not always, forward-looking statements are identified by the use of the future tense and by words such as “believes,” expects,” “anticipates,” “intends,” “will,” “may,” “could,” “would,” “projects,” “continues,” “estimates” or similar expressions. Forward-looking statements are not guarantees of future performance and actual results could differ materially from those indicated by the forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by the forward-looking statements.

The forward-looking statements contained or incorporated by reference in this document are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements include declarations regarding our plans, intentions, beliefs, or current expectations.

Among the important factors that could cause actual results to differ materially from those indicated by forward-looking statements are the risks and uncertainties described under “Risk Factors” in our Annual Report on Form 10-K for the year ended August 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on October 27, 2023, and elsewhere in this document and in our other filings with the SEC.

Forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and we do not undertake any obligation to update forward-looking statements to reflect new information, subsequent events, or otherwise.

Our historical results are not necessarily indicative of the results that may be expected for any period in the future.

Simulations Plus, Inc., incorporated in 1996, is a premier developer of drug discovery and development software for modeling and simulation, and for the prediction of molecular properties utilizing both artificial intelligence and machine-learning-based technology. We also provide consulting services ranging from early drug discovery through preclinical and clinical development analysis and for submissions to regulatory agencies. Our software and consulting services are provided to major pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and academic and regulatory agencies worldwide for use in the conduct of industry-based research. The Company is headquartered in Southern California, with offices in Buffalo, NY; Research Triangle Park, NC; Pittsburgh, PA; and Paris, France. Our common stock has traded on the Nasdaq Global Select Market under the symbol “SLP” since May 13, 2021, prior to which it traded on the Nasdaq Capital Market under the same symbol.

We are a global leader, delivering relevant, cost-effective software and creative and insightful consulting services. Pharmaceutical and biotechnology companies and hospitals use our software programs and scientific consulting services to guide early drug discovery (molecule design, screening, and lead optimization), preclinical and clinical development programs, and the development of generic medicines after patent expiration, including using our software products and services to enhance their understanding of the properties of potential new therapies and to use emerging data to improve formulations, select and justify dosing regimens, support the generic pharmaceutical product development industry, optimize clinical trial designs, and simulate outcomes in special populations, such as in elderly and pediatric patients.

Revenues increased by $2.5 million, or 21%, to $14.5 million for the three months ended November 30, 2023, compared to $12.0 million for the three months ended November 30, 2022. This increase is primarily due to an increase of $1.5 million, or 25%, in software-related revenue primarily due to higher revenue from GastroPlus® of $0.9 million and additional revenue from QSP Thales oncology model software of $0.7 million, as well as a $1.0 million, or 17%, increase in service-related revenue driven by the QSP services revenue of $1.1 million mostly due to the addition of Immunetrics services revenue, and higher revenues from PKPD of $0.3 million, offset by lower revenue from PBPK of $0.2 million.

Cost of revenues increased by $2.0 million, or 74%, for the three months ended November 30, 2023, compared to the three months ended November 30, 2022. The increase is primarily due to an increase of $1.9 million, or 105%, in service-related cost of revenue, driven by $1.2 million from the reorganization of our internal structure from divisions based on prior acquisitions to business units organized around key product and service offerings and $0.4 million from the acquisition of Immunetrics, which contributed to our services headcount. The new business unit structure is designed to optimize the utilization of our scientific talent in support of our revenue growth objectives.

Gross profit increased by $0.6 million, or 6%, to $9.8 million for the three months ended November 30, 2023, compared to $9.3 million, for the three months ended November 30, 2022. The increase in gross profit is primarily due to an increase in gross profit for our software business of $1.4 million, or 27%, reflecting the strong revenue growth and operating leverage of our software business, partially offset by a decrease in gross profit for our services business of $0.9 million, or 21%, reflecting the reorganization of our internal structure as well as additional services headcount from the Immunetrics acquisition.

Overall gross margin percentage was 68% and 78% for the three months ended November 30, 2023 and 2022, respectively.

We incurred $2.1 million of research and development costs during the three months ended November 30, 2023. Of this amount, $0.9 million was capitalized as a part of capitalized software development costs and $1.2 million was expensed. We incurred $2.1 million of research and development costs during the three months ended November 30, 2022. Of this amount, $0.9 million was capitalized and $1.2 million was expensed. Research and development spend remained relatively consistent with a slight increase of $0.1 million, or 5%, for the three months ended November 30, 2023, compared to the three months ended November 30, 2022.

Selling and marketing expenses increased by $0.5 million, or 34%, to $2.0 million for the three months ended November 30, 2023, compared to $1.5 million for the three months ended November 30, 2022. The increase was primarily due to higher marketing spend of $0.3 million, an increase in stock compensation of $0.1 million, and an increase of $0.1 million in sales commissions due to higher sales.

General, and administrative (“G&A”) expenses remained relatively consistent with a slight decrease of $0.1 million, or 1%, to $5.7 million for the three months ended November 30, 2023, compared to $5.8 million for the three months ended November 30, 2022.

Total other income was $1.4 million for the three months ended November 30, 2023, compared to total other income of $0.7 million for the three months ended November 30, 2022. The increase is primarily due to an increase in interest income of $0.5 million driven by an increase in interest rates as well as a decrease in the fair value of contingent consideration of $0.1 million related to the Immunetrics earnout liability.

The provision for income taxes was $0.5 million for the three months ended November 30, 2023, compared to $0.4 million for the three months ended November 30, 2022. Our effective tax rate decreased to 19% mainly due to disqualifying dispositions of incentive stock options for the three months ended November 30, 2023, when compared to 23% for the three months ended November 30, 2022.

Software Business

For the three months ended November 30, 2023, the revenue increase of $1.5 million, or 25%, compared to the three months ended November 30, 2022, was primarily due to higher revenue from GastroPlus® of $0.9 million and higher revenue from QSP Thales oncology model software of $0.7 million. Cost of revenues increased by $0.1 million, or 12%, during the same periods, and gross profit increased by $1.4 million, or 27%, for the three months ended November 30, 2023, compared to the three months ended November 30, 2022.

Services Business

For the three months ended November 30, 2023, the revenue increase of $1.0 million, or 17%, compared to the three months ended November 30, 2022, was primarily due to higher revenues from QSP services of $1.1 million driven by the addition of Immunetrics services revenue, and an increase in revenues from CPP services of $0.3 million, partially offset by a decrease in revenues from PBPK services of $0.2 million. Cost of revenues increased by $1.9 million, or 105%, driven by $1.2 million from the reorganization of our internal structure from divisions based on prior acquisitions to business units organized around key product and service offerings and $0.4 million from the acquisition of Immunetrics, which contributed to our services headcount. The new business unit structure is designed to optimize the utilization of our scientific talent in support of our revenue growth objectives. Gross profit decreased accordingly by $0.9 million, or 21%, for the same periods.

As of November 30, 2023, the Company had $39.8 million in cash and cash equivalents, $74.1 million in short-term investments, and working capital of $121.1 million. Our principal sources of capital have been a follow-on public offering in August 2020 for $107.7 million and cash flows from our operations. We have achieved continuous positive operating cash flow over the last fourteen fiscal years.

On December 29, 2022, our Board of Directors authorized and approved a share repurchase program for up to $50 million of the outstanding shares of our common stock, including the repurchase of up to $20 million of our outstanding shares through an accelerated share repurchase transaction. Under the repurchase program, shares may be repurchased at our discretion based on ongoing assessment of the capital needs of our business, the market price of shares of our common stock, and general market conditions. Repurchases may be made pursuant to certain SEC regulations, which permit common shares to be repurchased when we would otherwise be prohibited from doing so under insider-trading laws. There is no time limit in place for the completion of our share repurchase program, and the program may be suspended or discontinued at any time. Except as was required by the ASR Agreement (as defined below), we are not obligated to repurchase any shares under the repurchase program. We have funded share repurchases to date, and will fund future repurchases, if any, through cash on hand and cash generated from operations.

On January 11, 2023, the Company entered into an accelerated share repurchase agreement (the “ASR Agreement”) with Morgan Stanley & Co. LLC (“Morgan Stanley”) to repurchase an aggregate of $20 million of our outstanding shares of common stock. The ASR Agreement was executed as part of our existing $50 million share repurchase program. Pursuant to the terms of the ASR Agreement, we made an initial payment, using available cash balances, of $20 million to Morgan Stanley and received an initial delivery of 408,685 shares of Company common stock from Morgan Stanley. These 408,685 shares were retired and are treated as authorized, unissued shares. At final settlement on May 20, 2023, based on the volume-weighted average price of our common stock during the term of the ASR Agreement, Morgan Stanley delivered an additional 83,356 shares of Company common stock to us, which shares were also retired and treated as authorized, unissued shares. After completion of the repurchases under the ASR Agreement, $30 million remains available for additional repurchases under our authorized repurchase program.

On June 16, 2023, the Company acquired Immunetrics through a reverse triangular merger, pursuant to which Immunetrics became a wholly owned subsidiary of the Company. As consideration for the acquisition, at closing, the Company paid the equity holders of Immunetrics a cash payment in the aggregate amount of approximately $13.7 million, and also paid the representative of the Immunetrics stockholders $250,000 as an expense fund to cover expenses that it incurs in its role as such (collectively, the “Closing Payments”). In addition to the Closing Payments, the Company held back $1.8 million to cover any negative working capital adjustments and Immunetrics’ indemnification obligations under the Merger Agreement (the “Holdback Amount”), the balance of which, less any deductions, if any, will be distributed to the Immunetrics stockholders after expiration of the applicable hold back period. Furthermore, the Company agreed to pay the Immunetrics equity holders an aggregate amount of up to $8.0 million in earnout payments, consisting of two payouts of up to $4.0 million each, if Immunetrics achieves certain revenue milestones for the calendar years 2023 and 2024 (the “Earnout Payments,” and together with the Closing Payments and Holdback Amount, the “Merger Consideration”). Pursuant to the agreement, we have up to 60 days after December 31, 2023 to calculate and notify the Immunetrics stockholder representative of the amount of the first earnout payment, if any, payable for year one under the Agreement, after which the Immunetrics stockholder representative will have up to 25 days to provide any objections to our earnout calculations. We will have five business days from the earlier of (i) the date that the Immunetrics stockholder representative confirms agreement with our calculations and (ii) 25 days from the date we notify the Immunetrics stockholder representative of the calculated amount of the first earnout payment, provided that we do not receive any objections or confirmation of our calculations from the Immunetrics stockholder representative prior to expiration of the period. We have not yet determined the final amount, if any, we will be required to pay under the first earnout payment; however, we intend to do so within the period provided under the agreement.

We believe that our existing capital and anticipated funds from operations will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for the foreseeable future, including to complete the remaining $30 million of repurchases available under our $50 million share repurchase program, if we so choose. Thereafter, if cash generated from operations is insufficient to satisfy our capital requirements, we may have to sell additional equity or debt securities. In the event that additional financing is needed in the future, there can be no assurance that such financing will be available to us, or, if available, that it will be in amounts and on terms acceptable to us.

We continue to seek opportunities for strategic acquisitions, investments, and partnerships. If one or more such strategic opportunities are identified, a substantial portion of our cash reserves may be required to complete it; however, we intend to maintain sufficient cash reserves to provide reasonable assurance that outside financing will not be necessary to continue operations. If we identify an attractive strategic opportunity that would require more cash to complete than we are willing or able to use from our cash reserves, we will consider financing options to complete the transaction, including obtaining loans and issuing additional securities.

Except as discussed elsewhere in this Quarterly Report on Form 10-Q (this “Report”), we are not aware of any trends or demands, commitments, events, or uncertainties that are reasonably likely to result in a decrease in liquidity of our assets. The trend over the last ten years has been increasing cash deposits from our operating cash flows, and we expect that trend to continue for the foreseeable future.

Net cash provided by operating activities was $0.2 million for the three months ended November 30, 2023. Our operating cash flows resulted in part from our net income of $1.9 million, which was generated by cash received from our customers, offset by cash payments we made to third parties for their services and employee compensation. In addition, $3.3 million related to changes in balances of operating assets and liabilities was subtracted from net income and $1.5 million related to non-cash charges was added to net income to reconcile to cash flow from operations.

Net cash provided by operating activities was $4.7 million for the three months ended November 30, 2022. Our operating cash flows resulted primarily from our net income of $1.2 million, which was generated by cash received from our customers, offset by cash payments we made to third parties for their services and employee compensation. In addition, $1.5 million related to changes in balances of operating assets and liabilities was added to net income and $1.9 million related to noncash charges was added to net income to reconcile to cash flow from operations.

Net cash provided by operating activities decreased by $4.5 million during the three months ended November 30, 2023 compared to the three months ended November 30, 2022. $2.2 million of this change relates to accounts receivable, as the Company experienced strong cash collections from customers on older balances during the three months ended November 30, 2022. $0.8 million of this change relates to the Company's bonus payments, which increased during the three months ended November 30, 2023 due to growth in headcount and annual pay increases. $0.6 million of this change relates to the timing of our bi-weekly payroll such that 9 additional days were accrued for during the three months ended November 30, 2023.

Net cash used in investing activities during the three months ended November 30, 2023, was $16.9 million, primarily due to the purchase of short-term investments of $30.5 million and computer software development costs of $0.9 million, offset by proceeds from maturities of short-term investments of $14.8 million.

Net cash used in investing activities during the three months ended November 30, 2022, was $6.4 million, primarily due to the purchase of short-term investments of $29.5 million and computer software development costs of $0.9 million, offset by proceeds from maturities of short-term investments of $24.1 million.

Net cash used in financing activities during the three months ended November 30, 2023, was $1.0 million, primarily due to dividend payments totaling $1.2 million, partially offset by proceeds from the exercise of stock options totaling $0.2 million.

Net cash used in financing activities during the three months ended November 30, 2022, was $0.5 million, primarily due to payments on contracts payable of $0.8 million related to the Lixoft acquisition, and dividend payments totaling $1.2 million.

Refer to Note 5 – Shareholders’ Equity of the Notes to Financial Statements (Part II, Item 8 of this Report) for details regarding dividends.

We have seen some consolidation in the pharmaceutical industry during economic downturns, although these consolidations have not had a negative effect on our total revenues. Should customer delays, holds, program cancellations, or consolidations and downsizing in the industry continue to occur, those events could adversely impact our revenues and earnings going forward.

We believe that the need for improved productivity in the research and development activities directed toward developing new medicines will continue to result in increasing adoption of simulation and modeling tools and consulting services such as those we provide. New product developments in our pharmaceutical business segments could result in increased revenues and earnings if they are accepted by our markets; however, there can be no assurances that new products will result in significant improvements to revenues or earnings. For competitive reasons, we do not disclose all of our new product development activities.

The world has been affected by the ongoing conflict between Russia and Ukraine, the conflict between Israel and Hamas, other geopolitical instability, and general economic uncertainty, amongst other things. Inflation has risen, Federal Reserve interest rates have increased, and the general consensus among economists suggests that we should expect a recession risk to continue for the near future. These factors, amongst other things, could result in further economic uncertainty and volatility in the capital markets in the near term, and could negatively affect our operations.

Historically, we have paid cash dividends of $0.06 per share to holders of shares of our common stock on a quarterly basis. The declaration of any future dividends will be determined by our Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors.

Our continued quest for strategic acquisitions could result in a significant change to revenues and earnings if one or more such acquisitions are completed.

The potential for growth in new markets (e.g., healthcare) is uncertain. We will continue to explore these opportunities until such time as we either generate revenues in these new markets or determine that resources would be more efficiently used elsewhere.

The following table provides aggregate information regarding our contractual obligations as of November 30, 2023: